Gastric Carcinoma
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Gastric Carcinoma is a moderately active landscape with 32 programs across 19 companies. The most active players are Nanjing Sike Pharmaceutical Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 2 therapies are approved with 8 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Nanjing Sike Pharmaceutical Co., Ltd.
1 program
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
1 program
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
1 program
Innovent Biologics (Suzhou) Co. Ltd.
1 program
Eagle Vision Pharmaceutical Corp.
1 program
Regeneron
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
81%
Small molecule
30 of 37 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 37 pipeline programs.
Analysis
Trial Status
21
clinical trials
Clinical Trials
Trial Activity
21 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)